The Ionis spinout priced the IPO well below its target range but made up the shortfall by selling 62% more shares than it originally planned.

Qrativ is starting life with $8.3 million, access to its founders’ AI platform and clinical data and a remit to identify treatments for rare diseases.

The stock sale will set Alder up to forge ahead with development of a migraine drug it thinks can compete with rivals such as Amgen and Eli Lilly.

Upstart E-Scape Bio has closed an extension of its series A round, boosting its cash to $63 million.

Evelo Biosciences has raised $50 million to take its monoclonal microbials into the clinic.

We sat down with J&J Innovation to see what it wants from potential life science partners.

Zealand Pharma has become the latest European biotech to file for a Nasdaq IPO.

Caribou has seen biopharma vet and former Arrowhead exec Steven Kanner join the biotech.

Sienna Pharmaceuticals is joining the growing biotech IPO renaissance this year as it goes for a $75 million offering.

Venture Capital